Rathbones Group’s CRISPR Therapeutics CRSP Stock Holding History

Rathbones Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,097	Closed	-$201K	–	639
2025 Q3	$201K	Buy	+3,097	New	+$178K	﹤0.01%	581

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GSK plc London $602M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rathbones Group's CRSP Position: Q4 2025 in Review

Rathbones Group sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,097 shares — an estimated $201K sold.

Rathbones Group first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $201K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Rathbones Group reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Rathbones Group sold 3,097 CRISPR Therapeutics shares in Q4 2025, an estimated $201K.
Rathbones Group first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
Rathbones Group's CRISPR Therapeutics position peaked at $201K in Q3 2025.
480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Rathbones Group's 13F filing for Q4 2025, filed 21 Jan 2026.